State of Wisconsin Investment Board acquired a new position in Heska Corporation (NASDAQ:HSKA) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 5,000 shares of the medical research company’s stock, valued at approximately $510,000. State of Wisconsin Investment Board owned 0.07% of Heska Corporation at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Neuberger Berman Group LLC increased its holdings in Heska Corporation by 60.8% in the first quarter. Neuberger Berman Group LLC now owns 445,245 shares of the medical research company’s stock worth $46,742,000 after purchasing an additional 168,293 shares in the last quarter. Vanguard Group Inc. increased its holdings in Heska Corporation by 47.0% in the first quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after purchasing an additional 112,115 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in Heska Corporation in the first quarter worth approximately $5,853,000. Principal Financial Group Inc. bought a new stake in Heska Corporation in the first quarter worth approximately $5,234,000. Finally, Bank of New York Mellon Corp increased its holdings in Heska Corporation by 29.6% in the first quarter. Bank of New York Mellon Corp now owns 202,552 shares of the medical research company’s stock worth $21,264,000 after purchasing an additional 46,231 shares in the last quarter. Institutional investors and hedge funds own 81.44% of the company’s stock.

A number of equities research analysts have weighed in on HSKA shares. Benchmark Co. reiterated a “buy” rating and issued a $120.00 target price (up from $106.00) on shares of Heska Corporation in a report on Wednesday, August 9th. Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a report on Friday, August 4th. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Aegis lifted their target price on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, B. Riley reiterated a “neutral” rating and issued a $96.50 target price on shares of Heska Corporation in a report on Thursday, August 3rd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $105.20.

In other Heska Corporation news, EVP Nancy Wisnewski sold 825 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the completion of the sale, the executive vice president now owns 38,114 shares in the company, valued at approximately $3,895,631.94. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO John Mcmahon sold 2,608 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the sale, the chief financial officer now owns 193 shares of the company’s stock, valued at approximately $19,525.81. The disclosure for this sale can be found here. Company insiders own 14.70% of the company’s stock.

Shares of Heska Corporation (NASDAQ HSKA) opened at 97.28 on Wednesday. Heska Corporation has a one year low of $46.51 and a one year high of $115.00. The company has a market capitalization of $702.95 million, a P/E ratio of 49.58 and a beta of 0.91. The firm has a 50-day moving average price of $100.25 and a 200-day moving average price of $98.61.

Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The business had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $33.35 million. During the same quarter last year, the business posted $0.35 EPS. The business’s revenue was up 14.3% on a year-over-year basis. Equities analysts forecast that Heska Corporation will post $2.04 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/13/5000-shares-in-heska-corporation-hska-purchased-by-state-of-wisconsin-investment-board.html.

About Heska Corporation

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Institutional Ownership by Quarter for Heska Corporation (NASDAQ:HSKA)

Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.